Cover Image

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Hyeyeon Hong, Jonggi Choi
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
by: Jian Wang, et al.
Published: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply
by: WenXian OuYang, et al.
Published: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
by: Chen‐Pi Li, et al.
Published: (2024)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
by: Jonggi Choi
Published: (2025)

Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply
by: Eiichi Ogawa
Published: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B
by: Jing Li, et al.
Published: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
by: Elliot B. Tapper, et al.
Published: (2024)

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
by: Hye Won Lee, et al.
Published: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
by: Francisco Idalsoaga, et al.
Published: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
by: Kyle Staller, et al.
Published: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
by: Stuart McPherson, et al.
Published: (2024)

Higher end‐of‐treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg‐negative chronic hepatitis B patients stopping antivirals
by: Yen‐Chun Liu, et al.
Published: (2024)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
by: David Bergman, et al.
Published: (2024)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
by: Lukas Burghart, et al.
Published: (2024)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy—Authors' reply
by: Annalisa Schiepatti, et al.
Published: (2024)

Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find. Author's reply
by: Sagnik Biswas, et al.
Published: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply
by: Matthias Lenfant, et al.
Published: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
by: Abhinav Vasudevan, et al.
Published: (2024)

Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply
by: Matthias Lenfant, et al.
Published: (2024)

Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply
by: Jessica A. Fitzpatrick, et al.
Published: (2024)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply
by: Andrea Martini, et al.
Published: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
by: Sung Won Chung, et al.
Published: (2024)

Letter: Association between terlipressin and multidrug‐resistant organism rectal colonization: Authors' reply
by: Marcus M. Mücke, et al.
Published: (2024)

Editorial: How does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure? Authors' reply
by: Philip Vutien, et al.
Published: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
by: Jian Wang, et al.
Published: (2024)

Letter: Social work and clinical synergy—Optimizing health interventions for elderly DGBI populations: Authors' reply
by: Ami D. Sperber, et al.
Published: (2024)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
by: Arta Aliu, et al.
Published: (2024)

Letter: Over‐the‐scope clips in patients at high risk of rebleeding following upper gastrointestinal tract bleeding—The magic bullet for everyone? Authors'reply
by: Kai Song, et al.
Published: (2024)

Editorial: Quantity is important! Authors' reply
by: Marika Rudler, et al.
Published: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients—Authors' reply
by: Linda Henry, et al.
Published: (2024)

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply
by: María José García, et al.
Published: (2024)

Letter: Bif195 for aspirin‐induced gastric mucosal damage – More to do in further research. Authors' reply
by: Nina Løn, et al.
Published: (2024)

Letter: Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection
by: Jianrong Li, et al.
Published: (2024)

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH—Authors’ reply
by: S. K. Bansal, et al.
Published: (2024)

Letter: Enhancing gastric cancer prevention—The need for a comprehensive three‐tier emergency management strategy. Authors' reply
by: Irene Ligato, et al.
Published: (2024)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
by: Jian Wang, et al.
Published: (2024)

Editorial: Another brick in the CDST wall: Authors' reply
by: Kyuwon Kim, et al.
Published: (2024)

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply
by: Vibeke Strande, et al.
Published: (2024)

Letter: Ulcerative proctitis—A step towards addressing the knowledge gap, and a call for greater detail, in trial data—Authors' reply
by: Rocío Ferreiro‐Iglesias, et al.
Published: (2024)

Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2‐F3 fibrosis. Authors' reply
by: Stuart McPherson, et al.
Published: (2024)